Back to Agenda
Session 5: Leveraging Artificial Intelligence (AI) In Clinical Trials - Opportunities and Ethical Considerations
Session Chair(s)
Florian Lasch
Biostatistics Specialist, Data Analytics and Methods Task Force
European Medicines Agency, Netherlands
Gunilla Andrew-Nielsen
Head of Clinical Trials
Swedish Medical Products Agency (läkemedelsverket), Sweden
The recent advancements in artificial intelligence have ignited a surge of hope regarding its groundbreaking potential, while simultaneously raising concerns about the societal consequences it may bring.
This session explores the opportunities of artificial intelligence (AI) in medicines development and health care. As a counterpoint, the session delves into the ethical considerations surrounding AI-driven healthcare around fairness, privacy, and transparency. The panel discussion brings both perspectives together to explore harnessing the potential of AI in medicines development in an ethical way.
Speaker(s)
A Vision for AI Driven Health Care
Antonio Estrella
Taliossa, Singapore
Managing Director, Author, & Strategic Futurist,
Unlocking the Potential of AI in Medicines Development
Nicole Mahoney, PhD
Novartis Pharmaceuticals Corporation, United States
Executive Director US Regulatory Policy & Intelligence
Ensuring Ethical AI: Implications for Medicines Development
Arnaub Chatterjee, MHA, MPA
TriNetX, United States
Chief Product and Solutions Officer
Diversity in Clinical Trials
Karen Hicks, DrMed
FDA, United States
Deputy Director, Office of Medical Policy, CDER
Standing Together
Xiaoxuan Liu
Ophthalmology Doctor, University of Birmingham, United Kingdom
Senior Clinician Scientist in AI and Digital Health Technologies and an
Have an account?